Abstract
Objective To evaluate clinical remission in patients with small bowel Crohn′s disease(SBCD) who have received infliximab(IFX) therapy and to evaluate capsule endoscopy combined with ileocolonoscopy for mucosal healing at 14th week of IFX therapy. Methods Clinical data of 23 SBCD patients who received IFX were retrospectively analyzed. Laboratory indices [routine blood tests, C-reactive protein (CRP)and albumin], Crohn′s disease activity index (CDAI), Lewis score (LS), Crohn′s disease simplified endoscopic score (SES-CD), side effects and complications were compared before IFX treatment and at 14th week of IFX therapy. Results In 23 SBCD patients, both CDAI and CRP levels significantly decreased (P 135). Conclusion IFX plays a role in promoting clinical remission and mucosal healing in SBCD patients. Mucosal healing of CD patients in terminal ileum and other parts of small intestine are not synchronized. For CD patients with small bowel and colon involved, the evaluation of the whole gastrointestinal tract by capsule endoscopy combined with ileocolonoscopy is recommended on condition that they have no intestinal obstruction or severe stricture. Key words: Intestine, small; Crohn Disease; Capsule endoscopes; Infliximab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
